Eucreas Unjoni Ewropea - Finlandiż - EMA (European Medicines Agency)

eucreas

novartis europharm limited - vildagliptiini, metformiinihydrokloridia - diabetes mellitus, tyyppi 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Galvus Unjoni Ewropea - Finlandiż - EMA (European Medicines Agency)

galvus

novartis europharm limited - vildagliptiini - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Icandra (previously Vildagliptin / metformin hydrochloride Novartis) Unjoni Ewropea - Finlandiż - EMA (European Medicines Agency)

icandra (previously vildagliptin / metformin hydrochloride novartis)

novartis europharm limited - vildagliptiini, metformiinihydrokloridia - diabetes mellitus, tyyppi 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 käytettävissä olevista tiedoista eri yhdistelmistä).

Jalra Unjoni Ewropea - Finlandiż - EMA (European Medicines Agency)

jalra

novartis europharm limited - vildagliptiini - diabetes mellitus, tyyppi 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 käytettävissä olevista tiedoista eri yhdistelmistä).

Zomarist Unjoni Ewropea - Finlandiż - EMA (European Medicines Agency)

zomarist

novartis europharm limited  - vildagliptiini, metformiinihydrokloridia - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Xiliarx Unjoni Ewropea - Finlandiż - EMA (European Medicines Agency)

xiliarx

novartis europharm limited - vildagliptiini - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 käytettävissä olevista tiedoista eri yhdistelmistä).

Spirix 25 mg tabletti Finlandja - Finlandiż - Fimea (Suomen lääkevirasto)

spirix 25 mg tabletti

orifarm healthcare a/s - spironolactone - tabletti - 25 mg - spironolaktoni

Spirix 50 mg tabletti Finlandja - Finlandiż - Fimea (Suomen lääkevirasto)

spirix 50 mg tabletti

orifarm healthcare a/s - spironolactone - tabletti - 50 mg - spironolaktoni

ALEA COMP 20 mg / 5 mg / 12.5 mg tabletti, kalvopäällysteinen Finlandja - Finlandiż - Fimea (Suomen lääkevirasto)

alea comp 20 mg / 5 mg / 12.5 mg tabletti, kalvopäällysteinen

menarini international operations luxembourg s.a. - olmesartani medoxomilas,amlodipini besilas,hydrochlorothiazidum - tabletti, kalvopäällysteinen - 20 mg / 5 mg / 12.5 mg - olmesartaanimedoksomiili, amlodipiini ja hydroklooritiatsidi

ALEA COMP 40 mg / 5 mg / 12.5 mg tabletti, kalvopäällysteinen Finlandja - Finlandiż - Fimea (Suomen lääkevirasto)

alea comp 40 mg / 5 mg / 12.5 mg tabletti, kalvopäällysteinen

menarini international operations luxembourg s.a. - hydrochlorothiazidum,olmesartani medoxomilas,amlodipini besilas - tabletti, kalvopäällysteinen - 40 mg / 5 mg / 12.5 mg - olmesartaanimedoksomiili, amlodipiini ja hydroklooritiatsidi